Page 84 - 《中国药房》2024年1期

童难治性 IgA 肾病的疗效比较[J]. 中华肾脏病杂志， with idiopathic nephrotic syndrome[J]. Pharmacol Res，
2020，36（4）：264-270. 2011，63（5）：423-431.
WU H Y，GAO C L，FANG X，et al. Comparison of tacro‐ [13] WOILLARD J B，BADER-MEUNIER B，SALOMON R，
limus and mycophenolate mofetil in the treatment of et al. Pharmacokinetics of mycophenolate mofetil in chil‐
refractory IgA nephropathy children[J]. Chin J Nephrol， dren with lupus and clinical findings in favour of therapeu‐
2020，36（4）：264-270. tic drug monitoring[J]. Br J Clin Pharmacol，2014，78（4）：
[ 6 ] ZHOU P J，XU D，YU Z C，et al. Pharmacokinetics of 867-876.
mycophenolic acid and estimation of exposure using mul‐ [14] RONG Y，JUN H，KIANG T K L. Population pharmaco-
tiple linear regression equations in Chinese renal allograft kinetics of mycophenolic acid in paediatric patients[J]. Br
recipients[J]. Clin Pharmacokinet，2007，46（5）：389-401. J Clin Pharmacol，2021，87（4）：1730-1757.
[ 7 ] KUYPERS D R，MEUR Y L，CANTAROVICH M，et al. [15] MOULD D R，UPTON R N. Basic concepts in population
Consensus report on therapeutic drug monitoring of myco‐ modeling，simulation，and model-based drug development：
phenolic acid in solid organ transplantation[J]. Clin J Am part 2：introduction to pharmacokinetic modeling methods
Soc Nephrol，2010，5（2）：341-358. [J]. CPT Pharmacometrics Syst Pharmacol，2013，2（4）：
[ 8 ] BERGAN S，BRUNET M，HESSELINK D A，et al. Per‐ e38.
sonalized therapy for mycophenolate：consensus report by [16] ZHAO W，ELIE V，BAUDOUIN V，et al. Population
the International Association of Therapeutic Drug Moni‐ pharmacokinetics and Bayesian estimator of mycophe-
toring and Clinical Toxicology[J]. Ther Drug Monit， nolic acid in children with idiopathic nephrotic syndrome
2021，43（2）：150-200. [J]. Br J Clin Pharmacol，2010，69（4）：358-366.
[ 9 ] DONG M，FUKUDA T，COX S，et al. Population [17] MUKAKA M M. Statistics corner：a guide to appropriate
pharmacokinetic-pharmacodynamic modelling of myco‐ use of correlation coefficient in medical research[J]. Ma‐
phenolic acid in paediatric renal transplant recipients in lawi Med J，2012，24（3）：69-71.
the early post-transplant period[J]. Br J Clin Pharmacol， [18] ZENG L H，BLAIR E Y L，NATH C E，et al. Population
2014，78（5）：1102-1112. pharmacokinetics of mycophenolic acid in children and
[10] BARAU C，FURLAN V，DEBRAY D，et al. Population young people undergoing blood or marrow and solid
pharmacokinetics of mycophenolic acid and dose optimi‐ organ transplantation[J]. Br J Clin Pharmacol，2010，70
zation with limited sampling strategy in liver transplant （4）：567-579.
children[J]. Br J Clin Pharmacol，2012，74（3）：515-524. [19] VAN GELDER T. How cyclosporine reduces mycopheno‐
[11] KIM H，LONG-BOYLE J，RYDHOLM N，et al. Popula‐ lic acid exposure by 40% while other calcineurin inhibi‐
tion pharmacokinetics of unbound mycophenolic acid in tors do not[J]. Kidney Int，2021，100（6）：1185-1189.
pediatric and young adult patients undergoing allogeneic [20] LE W B，ZENG C H，LIU Z S，et al. Validation of the
hematopoietic cell transplantation[J]. J Clin Pharmacol， Oxford classification of IgA nephropathy for pediatric
2012，52（11）：1665-1675. patients from China[J]. BMC Nephrol，2012，13：158.
[12] SAINT-MARCOUX F，GUIGONIS V，DECRAMER S，et （收稿日期：2023-07-04 修回日期：2023-11-20）
al. Development of a Bayesian estimator for the therapeu‐ （编辑：曾海蓉）
tic drug monitoring of mycophenolate mofetil in children

· 74 · China Pharmacy 2024 Vol. 35 No. 1 中国药房 2024年第35卷第1期